Our new approach combines novel, custom-designed privileged chemotypes with deep behavioral profiling and brain circuit mapping.
To guide compound optimization for bipolar depression, we have developed a unique rodent behavioral “fingerprint” based on the drugs/drug combinations currently used to treat BPD patients.
In vivo systems neurobiology profiling confirmed that OAK-0011379 selectively activates appropriate mesolimbic and mesocortical brain circuits without modulation of dopamine centers associated with reward and addiction.
EEG brain-mapping studies in rats demonstrate an enhanced gamma band that is consistent with antidepressant action, attention and cognition and is ideally suited for use as a PD biomarker in Phase 1 clinical studies for bipolar disorder drugs.
Blue Oak anticipates submitting an investigational new drug (IND) application with the U.S. Food and Drug Administration in 2022.
Blue Oak research demonstrates that OAK-0011379 also has potential for the treatment of unipolar depression.